KOWA CO.,LTD. Logo

KOWA CO.,LTD.

A diversified manufacturer and trader in healthcare, optical products, and hospitality.

7807 | T

Overview

Corporate Details

ISIN(s):
JP3292900002
LEI:
Country:
Japan
Address:
堺市堺区海山町3丁159番地1

Description

Kowa Co., Ltd. is a diversified company that integrates manufacturing and trading operations across several business units. The company's trading arm manages the import, export, and sale of a wide range of products, including textiles, machinery, and construction materials. In the life science and healthcare sector, Kowa develops, manufactures, and markets pharmaceuticals, over-the-counter health products, and medical devices, with a notable specialization in ophthalmic diagnostic equipment. The company is also a prominent manufacturer of high-performance optical products, such as binoculars and spotting scopes, under its Prominar brand. Additionally, Kowa operates a hospitality business, managing hotels and other related services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-10-29 09:01
確認書
Japanese 8.0 KB
2021-10-29 09:00
訂正有価証券報告書-第34期(令和2年3月1日-令和3年2月28日)
Japanese 625.3 KB
2021-10-15 08:06
四半期報告書-第35期第2四半期(令和3年6月1日-令和3年8月31日)
Japanese 193.8 KB
2021-09-01 07:59
訂正四半期報告書-第35期第1四半期(令和3年3月1日-令和3年5月31日)
Japanese 123.2 KB
2021-07-15 08:52
四半期報告書-第35期第1四半期(令和3年3月1日-令和3年5月31日)
Japanese 162.1 KB
2021-05-28 08:04
内部統制報告書-第34期(令和2年3月1日-令和3年2月28日)
Japanese 22.7 KB
2021-05-28 08:02
確認書
Japanese 8.0 KB
2021-05-28 08:00
有価証券報告書-第34期(令和2年3月1日-令和3年2月28日)
Japanese 1.0 MB
2021-01-14 07:02
四半期報告書-第34期第3四半期(令和2年9月1日-令和2年11月30日)
Japanese 167.8 KB
2020-10-15 07:54
四半期報告書-第34期第2四半期(令和2年6月1日-令和2年8月31日)
Japanese 186.7 KB
2020-09-09 08:00
訂正有価証券報告書-第33期(平成31年3月1日-令和2年2月29日)
Japanese 606.7 KB
2020-07-15 10:03
四半期報告書-第34期第1四半期(令和2年3月1日-令和2年5月31日)
Japanese 152.6 KB
2020-06-30 10:01
有価証券報告書-第33期(平成31年3月1日-令和2年2月29日)
Japanese 990.0 KB
2020-01-14 07:01
四半期報告書-第33期第3四半期(令和1年9月1日-令和1年11月30日)
Japanese 169.4 KB
2019-10-15 08:00
四半期報告書-第33期第2四半期(2019/06/01-2019/08/31)
Japanese 206.3 KB

Automate Your Workflow. Get a real-time feed of all KOWA CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOWA CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOWA CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.